Preimplantation genetic testing for aneuploidy (PGT-A) in donor oocyte single blastocyst transfer cycles: is there benefit?

Preimplantation genetic testing for aneuploidy (PGT-A) in donor oocyte single blastocyst transfer cycles: is there benefit?
The use of PGT-A in donor oocyte cycles is increasing, however, its clinical benefit in these cycles is still unclear. A wide range of euploidy rates in blastocyst biopsies from donor oocyte cycles have been shown, from 39.5% to 82.5%1. Furthermore, implantation rates in women 40-43 years of age have been shown to be higher in PGT-A tested euploid embryos compared with unscreened embryos2, albeit with autologous oocytes. While these factors might make PGT-A appealing in donor oocyte cycles when average oocyte donor age is significantly younger than average recipient age, little is known about the impact of trophectoderm biopsy on implantation3.
Source: fertstert.org